Ataxia Centre, Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
Ataxia UK, London, UK.
BMJ Open. 2024 Sep 5;14(9):e084865. doi: 10.1136/bmjopen-2024-084865.
This study aims to assess the patient-reported benefits and the costs of coordinated care and multidisciplinary care at specialist ataxia centres (SACs) in the UK compared with care delivered in standard neurological clinics.
A patient survey was distributed between March and May 2019 to patients with ataxia or carers of patients with ataxia through the Charity Ataxia UK's mailing list, website, magazine and social media to gather information about the diagnosis, management of the ataxias in SAC and non-specialist settings, utilisation of various healthcare services and patients' satisfaction. We compared mean resource use for each contact type and health service costs per patient, stratifying patients by whether they were currently attending a SAC or never attended one.
Secondary care including SACs and general neurology clinics.
We had 277 participants in the survey, aged 16 years old and over, diagnosed with ataxia and living in the UK.
Patient experience and perception of the two healthcare services settings, patient level of satisfaction, difference in healthcare services use and costs.
Patients gave positive feedback about the role of SAC in understanding their condition (96.8% of SAC group), in coordinating referrals to other healthcare specialists (86.6%), and in offering opportunities to take part in research studies (85.2%). Participants who attended a SAC reported a better management of their symptoms and a more personalised care received compared with participants who never attended a SAC (p<0.001). Costs were not significantly different in between those attending a SAC and those who did not. We identified some barriers for patients in accessing the SACs, and some gaps in the care provided, for which we made some recommendations.
This study provides useful information about ataxia patient care pathways in the UK. Overall, the results showed significantly higher patient satisfaction in SAC compared with non-SAC, at similar costs. The findings can be used to inform policy recommendations on how to improve treatment and care for people with these very rare and complex neurological diseases. Improving access to SAC for patients across the UK is one key policy recommendation of this study.
本研究旨在评估英国专科共济失调中心(SAC)提供的协调护理和多学科护理相较于标准神经科诊所提供的护理,在患者报告的获益和成本方面的情况。
2019 年 3 月至 5 月,通过慈善共济失调协会的邮件列表、网站、杂志和社交媒体向共济失调患者或患者护理人员分发患者调查,以收集有关 SAC 和非专科环境下的共济失调诊断、管理、各种医疗保健服务的利用情况和患者满意度的信息。我们比较了每种接触类型的平均资源利用情况和每位患者的医疗保健服务成本,并根据患者是否正在 SAC 就诊或从未就诊进行分层。
包括 SAC 和一般神经病学诊所的二级保健。
我们的调查共有 277 名年龄在 16 岁及以上、在英国居住、被诊断为共济失调的参与者。
两种医疗服务设置的患者体验和感知、患者满意度、医疗服务利用和成本的差异。
患者对 SAC 在了解他们的病情(SAC 组 96.8%)、协调向其他医疗保健专家转诊(86.6%)以及提供参与研究机会(85.2%)方面的作用给予了积极反馈。与从未就诊于 SAC 的参与者相比,就诊于 SAC 的参与者报告称他们的症状得到了更好的管理,并且获得了更个性化的护理(p<0.001)。就诊于 SAC 和未就诊于 SAC 的患者之间的成本没有显著差异。我们发现患者在获得 SAC 服务方面存在一些障碍,并且在提供的护理方面存在一些差距,对此我们提出了一些建议。
本研究提供了有关英国共济失调患者护理途径的有用信息。总体而言,与非 SAC 相比,SAC 患者的满意度显著更高,而成本相似。研究结果可用于为如何改善这些非常罕见且复杂的神经疾病患者的治疗和护理提供政策建议。改善英国各地患者获得 SAC 的机会是本研究的一项关键政策建议。